None of the three compounds have human safety data in pregnancy or breastfeeding, and they are not FDA-approved
A person with a BMI of 28 and a history of gestational diabetes may benefit from one of these medications to lose weight while concomitantly mastering lifestyle behaviors, and then transition off the weight management medications to lifestyle alone, says Linda Gigliotti, MS, RDN, CDCES, CSOWM, an obesity and weight management specialist based in Irvine, California
The current story is still about trial results, safety review, and the path toward an FDA submission
In the type 2 diabetes mellitus population, 80% were treated with ACEi, ARB or ARNI, 84% with beta-blocker, 40% with MRA, and 98% with diuretic
Compounded semaglutide is semaglutide prepared by a licensed compounding pharmacy
The company's own disclosures are clear that their reported outcomes come from self-reported patient data collected through intake questionnaires every three to four weeks - not from independent clinical trials of the compounded formulations